Gheath Al-Atrash, Ph.D.
Affiliations: | 2002 | University of North Texas Health Science Center at Fort Worth |
Area:
Immunology, Oncology, Molecular BiologyGoogle:
"Gheath Al-Atrash"Parents
Sign in to add mentor| Ronald H. Goldfarb | grad student | 2002 | University of North Texas Health Science Center at Fort Worth | |
| (The urokinase plasminogen activator system in NK cells: Its role in invasion and its regulation by IL-2.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Saliba RM, Veltri L, Rondon G, et al. (2020) Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica |
| Srour SA, Saliba RM, Bittencourt MC, et al. (2019) Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation. American Journal of Hematology |
| Mehta RS, Bassett R, Olson A, et al. (2019) Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica |
| Popat UR, Saliba RM, Olson A, et al. (2019) Comparison of Tacrolimus and Post-Transplant Cyclophosphamide (PTCy) with Tacrolimus and Methotrexate (Tac/MTX) Gvhd Prophylaxis in Patients with AML Undergoing Transplantation from Matched Related or Unrelated Donors Biology of Blood and Marrow Transplantation. 25 |
| Kongtim P, Parmar S, Milton DR, et al. (2018) Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplantation |
| Ciurea SO, Bittencourt MCB, Milton DR, et al. (2018) Is a matched unrelated donor search needed for all allogeneic transplant candidates? Blood Advances. 2: 2254-2261 |
| Ciurea SO, Chilkulwar A, Saliba RM, et al. (2018) Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood |
| Battula VL, Le PM, Sun JC, et al. (2017) AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth. Jci Insight. 2 |
| Baran N, Han L, Herbrich S, et al. (2017) Novel Complex I inhibitor IACS-010759 Targets Leukemia Initiating Cells (LICs) in AML Patients Clinical Lymphoma Myeloma and Leukemia. 17: S297 |
| Andersson BS, Thall PF, Valdez BC, et al. (2016) Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplantation |